Alnylam Pharmaceuticals

Alnylam Pharmaceuticals is one of the...

• Russell 3000.

Alnylam Pharmaceuticals is a company listed under the stock ticker ALNY (US).

Alnylam Pharmaceuticals has a direct presence in 2 countries.

View the org chart displaying its 37 main executives

Most searched biographies at Alnylam Pharmaceuticals

• Yvonne Greenstreet, Chief Executive Officer and Director
• Amy Schulman, Chairman of the Board
• Carolyn Bertozzi, Director

Create your alert
to follow the executive moves at Alnylam Pharmaceuticals.

Alnylam Pharmaceuticals has 2,307 competitors including Eurofins (Luxembourg), Lonza (Switzerland) and Eurofins PSS Insourcing Solutions (United States (USA)).

Popular M&A news in Biotechnology

• Arca Biopharma and Oruka Therapeutics have announced they will merge  (posted on September 7 2024)..
• eGenesis has just announced a $191 Million fundraising (posted on September 6 2024).
• Zenas BioPharma has just announced a $100 Million fundraising (posted on August 25 2024).

Popular contacts in Biotechnology

• Kristina Burow - Director at Scholar Rock
• Ali Behbahani - Non-Executive Director at Adaptimmune Therapeutics
• Carl Gordon - Director at Adicet Bio

Learn more about the Biotechnology industry >

Press releases by Alnylam Pharmaceuticals

• Alnylam Presents Detailed Results from the Positive HELIOS-B Phase 3 Study of Vutrisiran▼ in Patients with A
• Alnylam to Webcast Presentations at Upcoming September Investor Conferences
• Alnylam Pharmaceuticals Reports Second Quarter 2024 Financial Results and Highlights Recent Period Activity
• Alnylam to Present Detailed Results from the HELIOS-B Phase 3 Study of Vutrisiran▼ in Patients with ATTR Amy
• Alnylam Reports Positive Topline Results from HELIOS-B Phase 3 Study of Vutrisiran, Achieving Statistical Sign
• Alnylam to Webcast Conference Call Discussing Second Quarter 2024 Financial Results
• Alnylam Issues 2023 Corporate Responsibility Report
• Alnylam Pharmaceuticals Reports First Quarter 2024 Financial Results and Highlights Recent Period Activity
• Alnylam to Webcast Conference Call Discussing First Quarter 2024 Financial Results
• Alnylam Presents Positive Results from the KARDIA-2 Phase 2 Study of Zilebesiran Added to Standard of Care Ant
• View more press releases Close

Social media about Alnylam Pharmaceuticals

• Alnylam Pharmaceuticals on Wikipedia, Google News & Yahoo Finance
• Alnylam Pharmaceuticals on LinkedIn, Twitter & YouTube

Contact by email its executives including Yvonne Greenstreet

Call Alnylam Pharmaceuticals at +1 617...

View the org chart

Register to receive your alert

Report an error